London, September 3, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Nevada finding that Hikma’s generic version of Vascepa® (icosapent ethyl) 1gm does not infringe any valid claim of six key Amarin-owned patents. Hikma received FDA approval for the product in May 2020 and is working towards a launch.
3 September 2020
Corporate, Press Release
Vascepa® is a prescription medicine that is indicated, in part, as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. According to IQVIA, US sales of Vascepa® were approximately $1.1 billion in the 12 months ending July 2020.
“We are very pleased with the Federal Circuit’s swift decision and to be one step closer to launching a generic version of this important medicine for US patients and healthcare providers, helping us to continue putting better health, within reach, every day,” said Brian Hoffmann, President of Hikma Generics. “Today’s decision demonstrates Hikma’s ability to successfully challenge patents on important medicines and to provide value to our customers and millions of patients across the United States.”